Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.72 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14049025 | 0.91 | SLC5A2 (0.75) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL1854535 | 0.91 | SLC5A2 (0.75) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL12426048 | 0.89 | SLC5A2 (0.65) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL1856494 | 0.89 | SLC5A2 (0.72) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL12426176 | 0.87 | SLC5A2 (0.69) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL1853237 | 0.86 | SLC5A2 (0.71) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL14049260 | 0.86 | SLC5A2 (0.68) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL12426158 | 0.86 | SLC5A2 (0.68) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL12426230 | 0.86 | SLC5A2 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL12426205 | 0.86 | SLC5A2 (0.64) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | claimed |
| EP-1980560-B1 | C-glycoside derivatives for the treatment of diabetes | ASTELLAS PHARMA INC (JP) | 2011-05-25 | — | — | EP | claimed |
| EP-1980560-A2 | C-glycoside derivatives for the treatment of diabetes | Astellas Pharma Inc. (JP) | 2008-10-15 | — | — | EP | claimed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-1980560-B1 | C-glycoside derivatives for the treatment of diabetes | ASTELLAS PHARMA INC (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-7772407-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772407-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885CHRM1 4519/4885 |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885CHRM1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.